Home › News › Clinical Trials › Archive

Clinical Trial News Archive

Get news By email or subscribe to our News feeds.

All News Consumer Pharma New Drugs Pipeline Clinical Trials

September 2007

September 4

Study Shows Combination Therapy Incorporating Avodart and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years Clinical Data Announces Positive Results from Phase III Pivotal Trial of Vilazodone for Depression NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher Sirolimus-Eluting Coronary Stent and Taxus Stent New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia SPP100 (Tekturna/Rasilez) Promising Results in Patients with Heart Failure Angiox (Bivalirudin) Alone Reduced Early Bleeding and Resulted in Similar One-Year Mortality Compared to Heparins Plus GP IIb/IIIa Combination Therapy in ACS Patients Undergoing Angioplasty Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER Sirolimus-eluting Coronary Stent Compared to Taxus Stent Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents Cypher Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety Cell That Triggers Symptoms in Allergy Attacks Can Also Limit Damage, Stanford Researchers Find Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds New Study Findings Confirm Clexane/Lovenox Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome Metabasis Therapeutics Announces Publication of Its Novel Computer-Aided Drug Design Technology for Drug Discovery in the Journal of the American Chemical Society Safety Profile of Taxus Liberte Stent System Highlighted in World's Largest Stent Registry Over 80% of Patients on ATC Achieve Undetectable HIV After 24 Weeks Pharmexa Presents Data from Malaria Vaccine on International Vaccine Conference PhytoMedical Releases Preliminary Research Results For New Class of Diabetes Compounds Major ADVANCE for Type 2 Diabetics New Study Demonstrates Patients Who Were Informed of Their Risk of Cardiovascular Disease Lowered Their Predicted Risk for Coronary Heart Disease Study Shows Rasilez, the First and Only Approved Direct Renin Inhibitor, Reduces a Marker of Heart Failure Severity and is Well-Tolerated First PAH Functional Class II Population Study Emphasizes Need to Diagnose and Treat PAH Early New Data On Orexin Receptor Antagonist Almorexant Shows Therapeutic Potential to Restore Normal Physiological Sleep in Patients Suffering From Insomnia Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension Roche's Tarceva Delivers Longer Life for Lung Cancer Patients American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure? Next Pharmaceuticals Announces Results of Relora Open Label Study

September 5

Depomed Announces Positive Results of Phase 2a Proof-of-Concept GERD Study Pharmacyclics Announces Encouraging Phase 2 Data With Xcytrin in Recurrent Non-Small Cell Lung Cancer Patients Salix Announces Statistically Significant Top-Line Results of a Unique Granulated Mesalamine Product Registration Study in Ulcerative Colitis Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Study Shows Iressa (Gefitinib) Is As Effective As Docetaxel In Pre-Treated Advanced NSCLC AKELA Pharma Inc. Announces Positive Results for The Extension Part of its Phase IIb Fentanyl Taifun Trial REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death Taxus Woman Study Reports Positive Clinical Outcomes for the Taxus Drug-eluting Stent in Women Stimuvax Phase II Data Highlight Three-Year Survival Results for Patients with Non-Small Cell Lung Cancer Genasense Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology Patients Who Switched from Established Lipitor Therapy to Simvastatin Experienced a Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death, New Observational Study Shows Pieris Validates the Use of Anticalins as Ophthalmologic Biotherapeutics Four Analyses of Three-Year Clinical Data Suggest CYPHER Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer International Stem Cell Corporation Creates Human Cornea Tissue from Its Parthenote Stem Cells; Preliminary Discovery Holds Promise to Aid in Therapy for Blindness Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806 Access and Somanta Announce New Data on Angiolix Humanized Monoclonal Antibody Stimuvax Therapeutic Cancer Vaccine – Phase II Data Highlight Three-Year Survival Results for Lung Cancer Patients Positive Survival Data from ASA404 Trial Presented at World Conference on Lung Cancer Genasense Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology DOR BioPharma Announces Publication Describing Protection Against Oral and Aerosol Ricin Exposure With Its Ricin Vaccine RiVax One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High New Data Show Olmesartan, an Angiotensin Receptor Blocker (ARB) Has Significant Anti-Atherosclerotic and Vascular Protective Effects

September 6

XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference Results from Study Evaluating Procrit in Intensive Care Unit Patients Published in New England Journal of Medicine The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia Idera Pharmaceuticals Presents Interim Data from Phase 1 Study Evaluating IMO-2055 in Combination with Gemcitabine and Carboplatin Link Uncovered Between Benign Prostatic Hyperplasia and NSAIDs, Says Harvard Men's Health Watch Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus - Sep 6, 2007 Boehringer Ingelheim to Initiate First Phase III Pivotal Study for New Oncology Compound BIBW 2992 Aranesp Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer Study Identifies Genetic Risk Factor for Rheumatoid Arthritis, Lupus Nymox BPH Drug Data Presentation September 8 at American Urological Association Meeting OSI Pharmaceuticals Announces Positive Results from a Metformin Drug Interaction Study with Its DP-IV Inhibitor, PSN9301

September 7

Arius Features Preclinical Data on Antibody Candidates at Two Conferences Genmab Announces Encouraging Preclinical Data for Ofatumumab OSI Pharmaceuticals Summarizes Data Presented on Tarceva (erlotinib) at the 12th World Congress on Lung Cancer Meeting Pharmexa Presents New Data from Two Experimental Flu Vaccines on International Vaccine Conference Pharmaceuticals Holding AG Publication in LANCET Neurology Highlights Potential of Santhera's SNT-MC17 for Friedreich's Ataxia Protox To Present Interim Prostate Cancer Data at AUA Conference Zemiva Normals Database From Molecular Insight Pharmaceuticals, Inc. Enables Accurate Determination of Abnormal Heart Activity Global Survey Reveals Significant Gap in Meeting World's Mental Health Care Needs Innogenetics Reports Top-line Results of Second Placebo-controlled Clinical Trial with Candidate Hepatitis C Therapeutic E1 Vaccine Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors Study Finds Heart Failure Is Rare Among Leukemia Patients on Imatinib

September 10

Regeneron Announces Positive Results in Exploratory Proof-of-Concept Study of Rilonacept in Chronic Active Gout Outcomes Data Demonstrating Prognostic Value of Cytogen's PROSTASCINT Published in Peer-Reviewed Journal Urology R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial New Global Alliance Unveils Integrated Strategy to Combat Neglected Diseases in The New England Journal of Medicine XenoPort Announces Results of a Phase 1 Clinical Trial and Plans for Additional Phase 2 Clinical Trials of XP19986 TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia Data in the SinuNase Phase 3 Clinical Trial Predicts That Virtually 100% of Chronic Sinusitis Cases Are Due to a Fungal-Induced Inflammation MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting Aspreva Provides Update On Lupus Nephritis Development Program Chelsea Therapeutics Resolves Bioavailability Issue and Reports Greater Than 10-Fold Improvement in Relative Bioavailability of New CH-1504 Formulation ValiRx - GeneICE & Cancer Research Technology Update Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease

September 11

Lev Pharmaceuticals, Inc. Phase III Clinical Update Conference Call NicOx Reports Topigen to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain Erbitux Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies Erbitux Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery Biothera's Imprime PGG Increases Efficacy of Erbitux against Non-Small Cell Lung Cancer, Study Finds Molecular Insight Pharmaceuticals, Inc. to Host Conference Call to Review Positive Zemiva Phase 2b Data Presented at ASNC Study Suggests Drug Used for Treatment for Heart Failure in Adults May Not Be Beneficial for Children and Teens Long-term Use of Glycemic Control Medication Rosiglitazone Associated with Increased Risk of Heart Attack and Heart Failure Glycemic Control Medication Pioglitazone Appears to Have Overall Favorable Effect Regarding Risk of Cardiovascular Events Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure

September 12

Hollis-Eden Pharmaceuticals Reports on Anti-Inflammatory Activity with HE3286 in Models of Diseases of Inflammation Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA) Reovirus Infection of Melanoma Cells Generates Anti-Tumour Immunity Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting Advitech Announces New Efficacy Results for Dermylex and Compliance with FDA Regulations on Claims Statistically Significant Efficacy of Juvista Demonstrated in Phase 2 Trial Using Drug Substance Manufactured by Lonza Biologics AVI BioPharma Drug Demonstrates Strong Survival Benefits and Elimination of Ebola Virus in Animals Customized Virus Kills Brain Tumor Stem Cells that Drive Lethal Cancer GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference Cognitive Activities Protect Against Alzheimer's -- Social and Physical Activities Not Enough Manic Phase of Bipolar Disorder Benefits from Breast Cancer Medication New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects

September 13

BiDil Data to be Presented at Heart Failure Society of America Science Meeting Raptor Pharmaceuticals Provides Update of Product Programs Optimer to Present Data on Lead Antibiotic Candidates at ICAAC Vernalis Announces Striking Weight Loss in Phase I Study with V24343 in Overweight and Mildly Obese Volunteers Genasense Clinical Data in Patients with Advanced Melanoma and Chronic Lymphocytic Leukemia to be Presented at ECCO Meeting in Barcelona Critical Therapeutics Announces Publication of Results from Two Asthma Studies Xanthus' Xanafide is Unaffected by Multi-Drug Resistance in In Vitro Preclinical Studies in Leukemia Cells Basilea Pharmaceutica Ltd. (CH) - New Data to be Presented on Key Basilea Compounds at the Interscience Conference on Antimicrobial Agents and Chemotherapy Genmab Provides Insights into IgG4 Antibodies

September 17

New Data for Galvus Provide Further Evidence of Robust Efficacy and Tolerability in Treating Patients with Type 2 Diabetes Immutep Announces That ImmuFact IMP321 Induces Activation of a Wide Range of Human Effector Cytotoxic Cells Trius Presents Study Results of Best-In-Class Antbiotics at ICAAC Sygnis’ AX200 shows efficacy in stroke patients – Phase IIa results exceed expectations New Data for Galvus Provide Further Evidence of Robust Efficacy and Tolerability in Treating Patients with Type 2 Diabetes Ligand Announces Positive Preclinical Data on Selective Androgen Receptor Modulator LGD-3303 Cholesterol Byproduct Blocks Heart-health Benefits of Estrogen Polydex Pharmaceuticals Limited announces BV Trial results Oculus Innovative Sciences Microcyn Technology Data to be Presented by Researchers at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Pervasis Therapeutics Announces New Animal Study Results Supporting Vascugel in Promoting Healing After Blood Vessel Injury Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Updated Revlimid Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia Nanoviricides Go Beyond Antibodies in Fighting Bird Flu Basilea Presents Research Data at ICAAC on Novel Antibiotic Addressing the Emerging Threat from Multi-resistant Gram-negative Bacteria Idera Pharmaceuticals Presents Preclinical Data on IMO-2125 and Other TLR9 Agonists Scientific Results Presented at ICAAC Demonstrate the Well-differentiated Profile and Broad Spectrum of BioAlliance Pharma's Antifungal Study Presented on Use of Cancidas (caspofungin acetate) as Empirical Therapy of Suspected Invasive Fungal Infections in Pediatric Patients with Persistent Fever and Neutropenia

September 18

First Osteoporosis Study in Patients with Hip Fracture Finds Once-Yearly Aclasta-Reclast Prevents Additional Fractures and Improves Survival New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years First Osteoporosis Study in Patients with Hip Fracture Finds Once-yearly Aclasta-reclast Prevents Additional Fractures and Improves Survival Aclidinium bromide demonstrates rapid and long-acting bronchodilatory effect in COPD Metabasis Therapeutics Presents Promising Preclinical Results with Its Novel Glucagon Antagonist for the Treatment of Type 2 Diabetes Study Presented on Use of Cancidas (caspofungin acetate) as Empirical Therapy of Suspected Invasive Fungal Infections in Pediatric Patients with Persistent Fever and Neutropenia Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of Velcade (Bortezomib) for Injection Based Therapy Across All Endpoints Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome Ardea Presents Early-Stage HIV Data at ICAAC New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA/ritonavir vs. KALETRA as Part of HIV Combination Therapy New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease Data Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Demonstrate That INCB9471 is a Potent, Selective Inhibitor of the HIV-1 Virus with Excellent Pharmacokinetics Suitable for Once-Daily Dosing Isentress (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 Weeks Provectus Pharmaceuticals, Inc. Releases Summary Results of Phase 1 Metastatic Melanoma Study Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug Selzentry (Maraviroc) Study Demonstrates Aerosolized Prolastin Using Unique Nebulizer Results in High Levels of Drug Deposited in Peripheral Regions of Lungs Results of Pre-Clinical Investigations of Ceragenix's Developmental Antibiotic to Be Presented at International Scientific Meeting on Infectious Diseases Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis RDEA806, A Potent, New HIV NNRTI With a High Genetic Barrier to Resistance and a Broad Spectrum of Activity, Introduced at 47th ICAAC Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA

September 19

Further Evidence for Lasting Immunological Efficacy of Diamyd Diabetes Vaccine Spectrum Pharmaceuticals Announces Presentation of SPI-1620 Data at the 10th International Conference on Endothelin Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation New Phase 3 Study In Treatment-Naïve Adults With HIV Evaluates Efficacy And Safety Of Once-Daily Prezista/Ritonavir Vs. Kaletra As Part Of HIV Combination Therapy Zelos Therapeutics Presents Positive Data at ASBMR on Subcutaneous and Inhaled Delivery of Cyclic PTH (1-31) (Ostabolin-C(TM)) News on HIV Gene Therapy Clinical Trial at ICAAC Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA Promising Early Data from Phase I/II Clinical Trial Using GenVec Vaccine Presented at Malaria Conference Results of Ceftobiprole Phase III Program for the Treatment of Complicated Skin Infections Presented Today at ICAAC CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein Biodel Inc. Announces VIAject Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC Enzo Biochem Reports Animal Study Supports Finding of New Therapeutics for Treating Periodontal Bone Loss Rimonabant Effectively Reduces Visceral Fat in the Obese Patient as Confirmed by Abdominal Computer Tomography (ct) Scan Appropriate Glycemic Control Contributes to Reducing the Risk of Macrovascular Diseases in Patients with Diabetes New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis Increased Bone Mineral Density Seen in Phase IIB Study with Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor Less Than One-Third of Women Aware of Landmark Hormone Therapy Study, Stanford Researcher Finds Preclinical Data on FermaVir's FV-100 Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study Metabasis Therapeutics Announces the First Publication on MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, in the Proceedings of the National Academy of Sciences Teva Provides Update on Edratide for Systemic Lupus Erythematosus Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models Actos (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes Arpida Presents Preclinical and Clinical Data on Iclaprim at Icaac Eclipse Data on Effects of Otsuka's Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients' Hemodynamics and Urine Output Featured in Heart Failure Society of America's Late Breaking Trials Dynavax's Heplisav Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial New Data Show That GlaxoSmithKline's Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile

September 20

Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza New Study Shows Once-Monthly Boniva is as Clinically Effective as Once-Weekly Fosamax at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis Medivir: MIV-701 Preclinical Efficacy Data Presented Arpida Presents Preclinical and Clinical Data on AR-709 at ICAAC New Data Confirm Clear Benefit of Protelos (Strontium Ranelate) in the Treatment of Postmenopausal Osteoporosis Study Shows Vasopressin Receptor Antagonist Vaprisol (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia Optimer Presents Positive Data on Two Lead Anti-Infective Drug Candidates Acceleron Pharma's ACE-011 Increases Bone Mineral Density and Bone Strength in Preclinical Studies in Non-Human Primates Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy A key sign of vascular aging, arterial stiffness, reduced by leading blood pressure medication Diovan®

September 25

Orexigen Announces Positive Clinical Results of Its Proprietary Naltrexone Sustained Release Formulation for Use in Contrave New Research Published on Impact of Targeting on Biodistribution and Efficacy of siRNA Using Calando Pharmaceuticals' siRNA Delivery Technology Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European College of Clinical Oncology Annual (ECCO) Meeting Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes Aranesp DAHANCA 10 Study Results Presented at ECCO Annual Meeting New Biomarker Data Links KRAS Gene to Vectibix Clinical Response Positive Xeloda Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting Data from Phase II Study of Gilead's Darusentan in Resistant Hypertension Published in Journal of Clinical Hypertension DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study GlaxoSmithKline Reports Positive New and Updated Data on Tyverb (lapatinib) at the 14th European Cancer Conference (ECCO) Alpharadin Treatment More Than Doubles Survival Rate in Prostate Cancer Patients BioAlliance Pharma: Results Presented at ECCO 2007 Further Confirm the Clinical Efficacy of BioAlliance Pharma's Antifungal, Particularly in Populations with High Risk of Candidiasis Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients Data From Ongoing Hematological Trials With Darinaparsin Presented at European College of Clinical Oncology Annual Meeting Arpida’s Extensive Presence at ICAAC Well-Received

September 26

CollaGenex Pharmaceuticals Announces Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Rosacea Promising Results in Treating Facial Bruising From Injectables Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) Alkermes and Indevus Announce Positive Results from Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD Herceptin Eradicates Tumours and May Reduce The Need for Mastectomies in women with inflammatory HER2-Positive Breast Cancer Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting CollaGenex Pharmaceuticals Announces Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Rosacea Phase 2 Study Suggests That Extended Dosing of Aranesp is as Efficacious as Weekly Dosing New Analysis Suggests First Cycle Use of Neulasta Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-induced Bowel Dysfunction in Patients with Chronic Severe Pain Incyte Reports Positive Proof-of-Concept Results For INCB18424, Its Lead JAK Inhibitor, and INCB13739, its Lead 11beta-HSD1 Inhibitor Alkermes and Indevus Announce Positive Results from Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD New Preliminary Phase II Data Show Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007 New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces Diamyd Diabetes Vaccine Effective for at Least 21 Months ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth Alnylam and Collaborators Publish New Paper in the Journal Nature on the In Vivo Efficacy and Safety of RNAi Therapeutics

September 27

Introgen Presents Biomarker Data Demonstrating Abnormal p53 Predicts ADVEXIN Efficacy in Head and Neck, Lung, Prostate and Li-Fraumeni Cancers Pharmacopeia Confirms Blockade of Angiotensin II Response with First-In-Class PS433540 (DARA) Positive Clinical Data On MediciNova's Product Candidate MN-029 Presented At the 14th European Cancer Conference (ECCO 14) Adventrx to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference Glufosfamide Results From Phase 3 Clinical Trial Presented at European Cancer Conference (ECCO) Nuvelo Announces Publication of NU206 Study Results in Proceedings of the National Academy of Sciences of the United States of America NKTR-102 (PEG-Irinotecan) Demonstrates Significant Anti-Tumor Activity and Improved Pharmacokinetic Profile in Preclinical Studies Presented at ECCO Palatin Technologies, Inc. Reports Positive Data from an At-home Study of Pre- and Postmenopausal Women with Female Sexual Arousal Disorder Treated with Bremelanotide ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates Study Shows Brostallicin in Combination with Cisplatin is Well-Tolerated and Produces Prolonged Disease Stabilization in Patients with Platinum-Resistant Cancers Nymox Announces BPH Drug Clinical Data Presentation Sept. 28 at American Urological Association Meeting New Scientific Data on Allergan's Botox (Botulinum Toxin Type A) Presented at the American Academy of Physical Medicine and Rehabilitation 68th Annual Assembly CDC Study Links Thimerosal in Vaccines to Motor/Phonic Tics and Deficits in Attention, Behavior Control, Verbal IQ

Clinical Trial Results Archive

2005

April

More News Resources

(web2)